olaparib,talazoparib,Enzalutamide
merck,pfizer,astrazeneca,astellas
['brca', 'talazo', 'crpc', 'olaparib']
the addition of talazoparib(parpi) to enza in crpc has most effect in brca+ve tumors. effects in the remaining hrr population are marginal or -ve (e.g. atm). this is largely consistent with previous data for parpi in crpc, supporting the odac decision on olaparib #asco2023 
Interested in Urology Cancers, biomarkers and drug development.